Helsinki: Doxorubicin treatment, which is commonly used in a variety of
cancers, leads to cardiac atrophy and body wasting. Researchers from the
Wihuri Research Institute and the University of Helsinki found that in
mouse heart, doxorubicin leads to blood vessel rarefaction, which was
prevented by treatment with gene therapy using the VEGF-B growth factor.